Cox Capital Mgt LLC grew its holdings in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 61.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 60,606 shares of the company's stock after buying an additional 23,137 shares during the period. AstraZeneca accounts for about 2.5% of Cox Capital Mgt LLC's holdings, making the stock its 13th largest holding. Cox Capital Mgt LLC's holdings in AstraZeneca were worth $3,971,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also made changes to their positions in AZN. McClarren Financial Advisors Inc. lifted its position in AstraZeneca by 320.8% in the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company's stock valued at $25,000 after acquiring an additional 247 shares during the last quarter. Capital Performance Advisors LLP acquired a new stake in shares of AstraZeneca during the third quarter worth about $28,000. Ashton Thomas Securities LLC acquired a new stake in shares of AstraZeneca during the third quarter worth about $45,000. Hollencrest Capital Management boosted its position in shares of AstraZeneca by 38.4% in the 3rd quarter. Hollencrest Capital Management now owns 692 shares of the company's stock valued at $54,000 after purchasing an additional 192 shares during the period. Finally, Versant Capital Management Inc boosted its position in shares of AstraZeneca by 2,618.5% in the 4th quarter. Versant Capital Management Inc now owns 734 shares of the company's stock valued at $48,000 after purchasing an additional 707 shares during the period. 20.35% of the stock is owned by institutional investors and hedge funds.
AstraZeneca Stock Performance
AstraZeneca stock traded up $0.31 during mid-day trading on Wednesday, reaching $65.68. 5,233,097 shares of the company were exchanged, compared to its average volume of 4,997,789. The firm has a market cap of $203.65 billion, a PE ratio of 31.43, a price-to-earnings-growth ratio of 1.19 and a beta of 0.46. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. The firm's 50-day simple moving average is $65.98 and its two-hundred day simple moving average is $74.69. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68.
AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, topping the consensus estimate of $1.01 by $0.03. The firm had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The company's revenue for the quarter was up 18.0% on a year-over-year basis. During the same period last year, the company earned $0.87 earnings per share. Equities analysts predict that AstraZeneca PLC will post 4.11 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of equities research analysts have weighed in on AZN shares. UBS Group upgraded AstraZeneca from a "sell" rating to a "neutral" rating in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a "sell" rating to a "hold" rating in a report on Wednesday, November 6th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, AstraZeneca has an average rating of "Buy" and an average target price of $89.75.
Read Our Latest Stock Analysis on AstraZeneca
About AstraZeneca
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Recommended Stories
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
